Scientia Advisors in the News

Businessweek quotes Harry Glorikian in "The Race for Diagnostic Tests for Alzheimer's"

Elizabeth Lopatto and Kanoko Matsuyama
July 15, 2010

The race is on to create a diagnostic test for Alzheimer's disease which would enable patients to start drug treatments earlier, participate in clinical trials for experimental medicines, and plan for their futures. General Electric, Bayer, and Avid Radiopharmaceuticals are all developing new diagnostic dyes for a market that could be worth $3 billion a year; with Avid aiming to submit an FDA application before yearend. "When you're running a marathon, it's hard to come from behind unless you're superior," says Harry Glorikian.

Read more about the players vying to be first to market with an early test for Alzheimer's at: Bloomberg Businessweek

SCIENTIA ADVISORS, LLC | info@scientiaadv.com

55 Cambridge Parkway, Suite 300E, Cambridge MA 02142 | Phone: 617-299-3000 | Fax: 617-812-0315